Innovative therapy for Classic Galactosemia - Tale of two HTS

Molecular Genetics and Metabolism

Volumn 105, Issue 1, 2012, Pages 44-55

  Tang, M ^a   Odejinmi, S I ^a   Vankayalapati, H ^b   Wierenga, K J ^c   Lai, K ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF UTAH   (United States)

^c UNIVERSITY OF OKLAHOMA COLLEGE OF MEDICINE   (United States)

Author keywords

Anti cancer therapy; Classic Galactosemia; Drug discovery; Galactokinase; High throughput screening; Small molecule inhibitors

Indexed keywords

ENZYME INHIBITOR; GALACTOKINASE; GALACTOKINASE INHIBITOR; GALACTOSE; GALACTOSE 1 PHOSPHATE URIDYLYLTRANSFERASE; GLUCOKINASE; HEXOKINASE; UNCLASSIFIED DRUG;

ADENOSINE DEAMINASE DEFICIENCY; ADRENOLEUKODYSTROPHY; ALPHA 1 ANTITRYPSIN DEFICIENCY; AUTOSOMAL RECESSIVE DISORDER; BONE MARROW TRANSPLANTATION; CARBOHYDRATE METABOLISM; CHAPERONE THERAPY; COFACTOR SUPPLEMENTATION; COMPUTER ANALYSIS; CYSTIC FIBROSIS; CYTOTOXICITY TEST; DIET RESTRICTION; DIET SUPPLEMENTATION; DRUG POTENCY; DUCHENNE MUSCULAR DYSTROPHY; ENZYME DEFICIENCY; ENZYME INHIBITION; ENZYME REPLACEMENT; EXON SKIPPING; FABRY DISEASE; GALACTOSEMIA; GENE THERAPY; GENETIC PROCEDURES; GOUT; HIGH THROUGHPUT SCREENING; HOMOCYSTINURIA; HUMAN; HURLER SYNDROME; IC 50; INBORN ERROR OF METABOLISM; LEBER CONGENITAL AMAUROSIS; LIVER TRANSPLANTATION; LYSOSOME STORAGE DISEASE; METHYLMALONIC ACIDURIA; NEWBORN MORBIDITY; NEWBORN SCREENING; PATHOPHYSIOLOGY; PHENYLKETONURIA; PRIORITY JOURNAL; REVIEW; RNA INTERFERENCE; SICKLE CELL ANEMIA; STOP CODON READ THROUGH; THERAPY; TYROSINEMIA; UREA CYCLE DISORDER;

GALACTOKINASE; GALACTOSEMIAS; HIGH-THROUGHPUT SCREENING ASSAYS; HUMANS; PROTEIN KINASE INHIBITORS; SMALL MOLECULE LIBRARIES;

EID: 84855344048     PISSN: 10967192     EISSN: 10967206     Source Type: Journal    
DOI: 10.1016/j.ymgme.2011.09.028     Document Type: Review

References (132)

1. Leloir L.F. The enzymatic transformation of uridine diphosphate glucose into a galactose derivative. Arch. Biochem. 1951, 33(2):186-190.
2. Acosta P.B., Gross K.C. Hidden sources of galactose in the environment. Eur. J. Pediatr. 1995, 154(7 Suppl. 2):S87-S92.
3. Berry G.T., et al. The effect of dietary fruits and vegetables on urinary galactitol excretion in galactose-1-phosphate uridyltransferase deficiency. J. Inherit. Metab. Dis. 1993, 16(1):91-100.
4. Berry G.T., et al. Endogenous synthesis of galactose in normal men and patients with hereditary galactosaemia. Lancet 1995, 346(8982):1073-1074.
5. Berry G.T., et al. The rate of de novo galactose synthesis in patients with galactose-1-phosphate uridyltransferase deficiency. Mol. Genet. Metab. 2004, 81(1):22-30.
6. Cardini C.E., Leloir L.F. Enzymic phosphorylation of galactosamine and galactose. Arch. Biochem. Biophys. 1953, 45(1):55-64.
7. Kalckar H.M., Braganca B., Munch-Petersen H.M. Uridyl transferases and the formation of uridine diphosphogalactose. Nature 1953, 172(4388):1038.
8. Leloir L.F. Enzymic isomerization and related processes. Adv. Enzymol. Relat. Subj. Biochem. 1953, 14:193-218.
9. Darrow R.A., Rodstrom R. Purification and properties of uridine diphosphate galactose 4-epimerase from yeast. Biochemistry 1968, 7(5):1645-1654.
10. Berry G.T., Elsas L.J. Introduction to the Maastricht workshop: lessons from the past and new directions in galactosemia. J. Inherit Metab. Dis. 2011 Apr, 34(2):249-255.
11. Fridovich-Keil J., Walter J. Chapter 72: Galactosemia in Online Metabolic and Molecular Bases of Inherited Diseases-OMMBID 2008, McGraw-Hill, New York. http://www.ommbid.com, D. Valle (Ed.).
12. Lai K., Elsas L.J., Wierenga K.J. Galactose toxicity in animals. IUBMB Life 2009, 61(11):1063-1074.
13. Segal S., Berry G.T. Disorders of galactose metabolism. The Metabolic Basis of Inherited Diseases 1995, 967-1000. McGraw-Hill, New York. C.R. Scriver (Ed.).
14. McCorvie T.J., Timson D.J. The structural and molecular biology of type I galactosemia: enzymology of galactose 1-phosphate uridylyltransferase. IUBMB Life 2011 Jul 25, [Epub ahead of print]. 10.1002/iub.511.
15. Kaye C.I., et al. Newborn screening fact sheets. Pediatrics 2006, 118(3):e934-e963.
16. Donnell G.N., et al. Galactose-1-phosphate in galactosemia. Pediatrics 1963, 31:802-810.
17. Gitzelmann R. Galactose-1-phosphate in the pathophysiology of galactosemia. Eur. J. Pediatr. 1995, 154(7 Suppl. 2):S45-S49.
18. Abukawa D., Ohura T., Tazawa Y. Disorders of fructose and galactose metabolism. Ryoikibetsu Shokogun Shirizu 1995, 8:371-374.
19. Waisbren S.E., et al. The adult galactosemic phenotype. J. Inherit. Metab. Dis. 2011 Jul 21, [Epub ahead of print].
20. Waggoner D. Buist, NRM, long-term complications in treated galactosemia - 175 U.S. cases. Int. Pediatr. 1993, 8:97-100.
21. Gitzelmann R., Wells H.J., Segal S. Galactose metabolism in a patient with hereditary galactokinase deficiency. Eur. J. Clin. Invest. 1974, 4(2):79-84.
22. Gitzelmann R. Formation of galactose-1-phosphate from uridine diphosphate galactose in erythrocytes from patients with galactosemia. Pediatr. Res. 1969, 3(4):279-286.
23. Lai K., Elsas L.J. Overexpression of human UDP-glucose pyrophosphorylase rescues galactose-1-phosphate uridyltransferase-deficient yeast. Biochem. Biophys. Res. Commun. 2000, 271(2):392-400.
24. Lai K., et al. GALT deficiency causes UDP-hexose deficit in human galactosemic cells. Glycobiology 2003, 13(4):285-294.
25. Mehta D.V., Kabir A., Bhat P.J. Expression of human inositol monophosphatase suppresses galactose toxicity in Saccharomyces cerevisiae: possible implications in galactosemia. Biochim. Biophys. Acta 1999, 1454(3):217-226.
26. Bhat P.J. Galactose-1-phosphate is a regulator of inositol monophosphatase: a fact or a fiction?. Med. Hypotheses 2003, 60(1):123-128.
27. Parthasarathy R., Parthasarathy L., Vadnal R. Brain inositol monophosphatase identified as a galactose 1-phosphatase. Brain Res. 1997, 778(1):99-106.
28. Slepak T.I., et al. Involvement of endoplasmic reticulum stress in a novel Classic Galactosemia model. Mol. Genet. Metab. 2007, 92(1-2):78-87.
29. Stempfel R.S., Sidbury J.B., Migeon C.J. Beta-glucuronidase hydrolysis of urinary corticosteroid conjugates: the effect of salicylate glucuronoside as a competing substrate and the effect of enzyme inactivation. J. Clin. Endocrinol. Metab. 1960, 20:814-824.
30. Maddaiah V.T., Madsen N.B. Kinetics of purified liver phosphorylase. J. Biol. Chem. 1966, 241(17):3873-3881.
31. Kalckar H.M., Maxwell E.S. Biosynthesis and metabolic function of uridine diphosphoglucose in mammalian organisms and its relevance to certain inborn errors. Physiol. Rev. 1958, 38(1):77-90.
32. Charlwood J., et al. Defective galactosylation of serum transferrin in galactosemia. Glycobiology 1998, 8(4):351-357.
33. Jaeken J., Kint J., Spaapen L. Serum lysosomal enzyme abnormalities in galactosaemia. Lancet 1992, 340(8833):1472-1473.
34. Prestoz L.L., et al. Altered follicle stimulating hormone isoforms in female galactosaemia patients. Eur. J. Pediatr. 1997, 156(2):116-120.
35. Berry G.T. The unexplored potential of the pentose phosphate pathway in health and disease. J. Inherit. Metab. Dis. 2008, 31(6):661.
36. Berry G.T. Is prenatal myo-inositol deficiency a mechanism of CNS injury in galactosemia?. J. Inherit. Metab. Dis. 2011, 34(2):345-355.
37. Wells W.W., et al. The isolation and identification of galactitol from the brains of galactosemia patients. J. Biol. Chem. 1965, 240:1002-1004.
38. Quan-Ma R., Wells W.W. The distribution of galactitol in tissues of rats fed galactose. Biochem. Biophys. Res. Commun. 1965, 20(4):486-490.
39. Dahl S.C., Handler J.S., Kwon H.M. Hypertonicity-induced phosphorylation and nuclear localization of the transcription factor TonEBP. Am. J. Physiol. Cell Physiol. 2001, 280(2):C248-C253.
40. Jeon U.S., et al. How tonicity regulates genes: story of TonEBP transcriptional activator. Acta Physiol. (Oxf) 2006, 187(1-2):241-247.
41. Miyakawa H., et al. Tonicity-responsive enhancer binding protein, a rel-like protein that stimulates transcription in response to hypertonicity. Proc. Natl. Acad. Sci. U. S. A. 1999, 96(5):2538-2542.
42. Irarrazabal C.E., et al. Activator protein-1 contributes to high NaCl-induced increase in tonicity-responsive enhancer/osmotic response element-binding protein transactivating activity. J. Biol. Chem. 2008, 283(5):2554-2563.
43. Berry G.T., et al. The human osmoregulatory Na+/myo-inositol cotransporter gene (SLC5A3): molecular cloning and localization to chromosome 21. Genomics 1995, 25(2):507-513.
44. Tsui M.M., York J.D. Roles of inositol phosphates and inositol pyrophosphates in development, cell signaling and nuclear processes. Adv. Enzyme Regul. 2010, 50(1):324-337.
45. Yuan T.L., Cantley L.C. PI3K pathway alterations in cancer: variations on a theme. Oncogene 2008, 27(41):5497-5510.
46. Osaki M., Oshimura M., Ito H. PI3K-Akt pathway: its functions and alterations in human cancer. Apoptosis 2004, 9(6):667-676.
47. Berry G.T., et al. Loss of murine Na+/myo-inositol cotransporter leads to brain myo-inositol depletion and central apnea. J. Biol. Chem. 2003, 278(20):18297-18302.
48. Berry G.T. Galactosemia and amenorrhea in the adolescent. Ann. N. Y. Acad. Sci. 2008, 1135:112-117.
49. Agam G., et al. Knockout mice in understanding the mechanism of action of lithium. Biochem. Soc. Trans. 2009, 37(Pt 5):1121-1125.
50. Murata M., et al. The role of aldose reductase in sugar cataract formation: aldose reductase plays a key role in lens epithelial cell death (apoptosis). Chem. Biol. Interact. 2001, 130-132(1-3):617-625.
51. Kubo E., et al. Cataract formation through the polyol pathway is associated with free radical production. Exp. Eye Res. 1999, 68(4):457-464.
52. Gitzelmann R. Deficiency of erythrocyte galactokinase in a patient with galactose diabetes. Lancet 1965, 2(7414):670-671.
53. Gitzelmann R. Letter: additional findings in galactokinase deficiency. J. Pediatr. 1975, 87(6 Pt 1):1007-1008.
54. Bosch A.M. Classical galactosaemia revisited. J. Inherit. Metab. Dis. 2006, 29(4):516-525.
55. Fridovich-Keil J. Toward Improved Intervention for Galactosemia Available from:. http://www.galactosemia.org/PGC_awards.asp.
56. Timson D.J. GHMP kinases - structures mechanisms and potential for therapeutically relevant inhibition. Curr. Enzym. Inhib. 2007, 3:77-94.
57. Wierenga K.J., et al. High-throughput screening for human galactokinase inhibitors. J. Biomol. Screen. 2008, 13(5):415-423.
58. Walter J., Wraith J.E. Chapter 5: Treatment: Present Status and New Trends in Metabolic Diseases-Diagnosis and Treatment 2006, Springer Medizin Verlag. 4th ed.
59. Saudubray J.M., et al. Chapter 1: a clinical approach to inherited metabolic diseases. Inborn Metabolic Diseases - Diagnosis and Treatment 2006, Springer Medizin Verlag. 4th ed.
60. Souillet G., et al. Outcome of 27 patients with Hurler's syndrome transplanted from either related or unrelated haematopoietic stem cell sources. Bone Marrow Transplant. 2003, 31(12):1105-1117.
61. Staba S.L., et al. Cord-blood transplants from unrelated donors in patients with Hurler's syndrome. N. Engl. J. Med. 2004, 350(19):1960-1969.
62. Hsieh M.M., Fitzhugh C.D., Tisdale J.F. Allogeneic hematopoietic stem cell transplant for sickle cell disease: the time is now. Blood 2011 Aug 4, 118(5):1197-1207.
63. Johnson F.L., et al. Bone-marrow transplantation in a patient with sickle-cell anemia. N. Engl. J. Med. 1984, 311(12):780-783.
64. Ariga T. Gene therapy for adenosine deaminase (ADA) deficiency: review of the past, the present and the future. Nihon Rinsho 2001, 59(1):72-75.
65. Blaese R.M., et al. T lymphocyte-directed gene therapy for ADA-SCID: initial trial results after 4 years. Science 1995, 270(5235):475-480.
66. Maguire A.M., et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: a phase 1 dose-escalation trial. Lancet 2009, 374(9701):1597-1605.
67. Cartier N., et al. Hematopoietic stem cell gene therapy with a lentiviral vector in X-linked adrenoleukodystrophy. Science 2009, 326(5954):818-823.
68. Seregin S.S., Amalfitano A. Gene therapy for lysosomal storage diseases: progress, challenges and future prospects. Curr. Pharm. Des. 2011 Jul 21, [Epub ahead of print].
69. Park I.H., et al. Reprogramming of human somatic cells to pluripotency with defined factors. Nature 2008, 451(7175):141-146.
70. Yu J., et al. Induced pluripotent stem cell lines derived from human somatic cells. Science 2007, 318(5858):1917-1920.
71. Kim J.B., et al. Pluripotent stem cells induced from adult neural stem cells by reprogramming with two factors. Nature 2008, 454(7204):646-650.
72. Mohamadnejad M., Swenson E.S. Induced pluripotent cells mimicking human embryonic stem cells. Arch. Iran. Med. 2008, 11(1):125-128.
73. Kishore R., Krishnamurthy P., Losordo D.W. Career moves: induced pluripotent cells from human aortic smooth muscle cells can efficiently redifferentiate into parental phenotype. Circ. Res. 2010, 106(1):7-9.
74. Hanna J., et al. Treatment of sickle cell anemia mouse model with iPS cells generated from autologous skin. Science 2007, 318(5858):1920-1923.
75. Goemans N.M., et al. Systemic administration of PRO051 in Duchenne's muscular dystrophy. N. Engl. J. Med. 2011, 364(16):1513-1522.
76. Howard M.T., et al. Sequence specificity of aminoglycoside-induced stop condon readthrough: potential implications for treatment of Duchenne muscular dystrophy. Ann. Neurol. 2000, 48(2):164-169.
77. Buck N.E., et al. Stop codon read-through of a methylmalonic aciduria mutation. Mol. Genet. Metab. 2009, 97(4):244-249.
78. Kaler S.G., et al. Translational read-through of a nonsense mutation in ATP7A impacts treatment outcome in Menkes disease. Ann. Neurol. 2009, 65(1):108-113.
79. Hein L.K., et al. Alpha-l-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J. Mol. Biol. 2004, 338(3):453-462.
80. Sato A., et al. Small interfering RNA delivery to the liver by intravenous administration of galactosylated cationic liposomes in mice. Biomaterials 2007, 28(7):1434-1442.
81. Kakkis E.D., et al. Long-term and high-dose trials of enzyme replacement therapy in the canine model of mucopolysaccharidosis I. Biochem. Mol. Med. 1996, 58(2):156-167.
82. Germain D.P., et al. Enzyme replacement therapy of lysosomal storage diseases. Rev. Med. Interne 2010, 31(Suppl 2):S279-S291.
83. Schiffmann R., et al. Enzyme replacement therapy in Fabry disease: a randomized controlled trial. JAMA 2001, 285(21):2743-2749.
84. Eng C.M., et al. A phase 1/2 clinical trial of enzyme replacement in fabry disease: pharmacokinetic, substrate clearance, and safety studies. Am. J. Hum. Genet. 2001, 68(3):711-722.
85. Arikan-Ayyildiz Z., et al. Immunoglobulin abnormalities and effects of enzyme replacement therapy in children with Gaucher disease. Pediatr. Blood Cancer 2011 Apr, 56(4):664-666.
86. Kang T.S., et al. Converting an injectable protein therapeutic into an oral form: phenylalanine ammonia lyase for phenylketonuria. Mol. Genet. Metab. 2010, 99(1):4-9.
87. Sampson H.M., et al. Identification of a NBD1-binding pharmacological chaperone that corrects the trafficking defect of F508del-CFTR. Chem. Biol. 2011, 18(2):231-242.
88. Kuznetsov G., Nigam S.K. Folding of secretory and membrane proteins. N. Engl. J. Med. 1998, 339(23):1688-1695.
89. McCully K.S. Homocysteine, vitamins, and vascular disease prevention. Am. J. Clin. Nutr. 2007, 86(5):1563S-1568S.
90. Shintaku H., et al. Long-term treatment and diagnosis of tetrahydrobiopterin-responsive hyperphenylalaninemia with a mutant phenylalanine hydroxylase gene. Pediatr. Res. 2004, 55(3):425-430.
91. Lindstedt S., et al. Treatment of hereditary tyrosinaemia type I by inhibition of 4-hydroxyphenylpyruvate dioxygenase. Lancet 1992, 340(8823):813-817.
92. Yue T.F., Gutman A.B. Effect of allopurinol (4-hydroxypyrazolo-(3,4-d)pyrimidine) on serum and urinary uric acid in primary and secondary gout. Am. J. Med. 1964, 37:885-898.
93. Daniotti M., et al. New developments in the treatment of hyperammonemia: emerging use of carglumic acid. Int. J. Gen. Med. 2011, 4:21-28.
94. van Spronsen F.J., et al. Phenylketonuria: tyrosine supplementation in phenylalanine-restricted diets. Am. J. Clin. Nutr. 2001, 73(2):153-157.
95. Batshaw M.L., Brusilow S.W. Evidence of lack of toxicity of sodium phenylacetate and sodium benzoate in treating urea cycle enzymopathies. J. Inherit. Metab. Dis. 1981, 4(4):231.
96. Batshaw M.L., et al. Therapy of urea cycle enzymopathies: three case studies. Johns Hopkins Med. J. 1981, 148(1):34-40.
97. Holton J.B., de la Cruz F., Levy H.L. Galactosemia: the uridine diphosphate galactose deficiency-uridine treatment controversy. J. Pediatr. 1993, 123(6):1009-1014.
98. Sudha K.N., et al. Virtual screening for novel COX-2 inhibitors using the ZINC database. Bioinformation 2008, 2(8):325-329.
99. Thoden J.B., et al. Molecular structure of human galactokinase: implications for type II galactosemia. J. Biol. Chem. 2005, 280(10):9662-9670.
100. Bork P., Sander C., Valencia A. Convergent evolution of similar enzymatic function on different protein folds: the hexokinase, ribokinase, and galactokinase families of sugar kinases. Protein Sci. 1993, 2(1):31-40.
101. Tang M., et al. Molecular and biochemical characterization of human galactokinase and its small molecule inhibitors. Chem. Biol. Interact. 2010, 188(3):376-385.
102. Thoden J.B., Holden H.M. Molecular structure of galactokinase. J. Biol. Chem. 2003, 278(35):33305-33311.
103. Timson D.J. GHMP kinases - structures, mechanisms and potential for therapeutically relevant inhibition. Curr. Enzym. Inhib. 2007, 3(1):77-94.
104. Timson D.J., Reece R.J. Functional analysis of disease-causing mutations in human galactokinase. Eur. J. Biochem. 2003, 270(8):1767-1774.
105. Timson D.J., Reece R.J. Sugar recognition by human galactokinase. BMC Biochem. 2003, 4:16.
106. Debouck C., et al. Structure of the galactokinase gene of Escherichia coli, the last (?) gene of the gal operon. Nucleic Acids Res. 1985, 13(6):1841-1853.
107. Andreassi J.L., et al. Crystal structure of the Streptococcus pneumoniae mevalonate kinase in complex with diphosphomevalonate. Protein Sci. 2007, 16(5):983-989.
108. Odejinmi S., et al. Structure-activity analysis and cell-based optimization of human galactokinase inhibitors. ACS Med. Chem. Lett. 2011, 2(9):667-672.
109. Edwards P.A., Ericsson J. Signaling molecules derived from the cholesterol biosynthetic pathway: mechanisms of action and possible roles in human disease. Curr. Opin. Lipidol. 1998, 9(5):433-440.
110. Miallau L., et al. Biosynthesis of isoprenoids: crystal structure of 4-diphosphocytidyl-2C-methyl-d-erythritol kinase. Proc. Natl. Acad. Sci. U. S. A. 2003, 100(16):9173-9178.
111. Sacchettini J.C., Poulter C.D. Creating isoprenoid diversity. Science 1997, 277(5333):1788-1789.
112. Balibar C.J., Shen X., Tao J. The mevalonate pathway of Staphylococcus aureus. J. Bacteriol. 2009, 191(3):851-861.
113. Goldstein J.L., Brown M.S. Regulation of the mevalonate pathway. Nature 1990, 343(6257):425-430.
114. Smit A., Mushegian A. Biosynthesis of isoprenoids via mevalonate in Archaea: the lost pathway. Genome Res. 2000, 10(10):1468-1484.
115. Dubey V.S., Bhalla R., Luthra R. An overview of the non-mevalonate pathway for terpenoid biosynthesis in plants. J. Biosci. 2003, 28(5):637-646.
116. Eisenreich W., et al. Biosynthesis of isoprenoids via the non-mevalonate pathway. Cell Mol. Life Sci. 2004, 61(12):1401-1426.
117. Hunter W.N. The non-mevalonate pathway of isoprenoid precursor biosynthesis. J. Biol. Chem. 2007, 282(30):21573-21577.
118. Lichtenthaler H.K., et al. The non-mevalonate isoprenoid biosynthesis of plants as a test system for new herbicides and drugs against pathogenic bacteria and the malaria parasite. Z. Naturforsch. C 2000, 55(5-6):305-313.
119. Eoh H., Brennan P.J., Crick D.C. The Mycobacterium tuberculosis MEP (2C-methyl-d-erythritol 4-phosphate) pathway as a new drug target. Tuberculosis (Edinb) 2009, 89(1):1-11.
120. Boucher Y., Doolittle W.F. The role of lateral gene transfer in the evolution of isoprenoid biosynthesis pathways. Mol. Microbiol. 2000, 37(4):703-716.
121. Tang M., et al. Identification and Identification of novel small molecule inhibitors of 4-disphosphocytidyl-2-C-methyl D-erythritol (CDP-ME) kinase of Gram-negative bacteria. Bioorg. Med. Chem. 2011 Oct 1, 19(19):5886-5895. [Epub 2011 Aug 16].
122. Cheng G.Z., et al. Advances of AKT pathway in human oncogenesis and as a target for anti-cancer drug discovery. Curr. Cancer Drug Targets 2008, 8(1):2-6.
123. Brace, A., et al., GALK1s as modifiers of the PTEN/AKT Pathway and methods of use (US Patent Application Publication - Application#11/993,191), July 22, 2010: USA.
124. Antshel K.M., Epstein I.O., Waisbren S.E. Cognitive strengths and weaknesses in children and adolescents homozygous for the galactosemia Q188R mutation: a descriptive study. Neuropsychology 2004, 18(4):658-664.
125. Bosch A.M., et al. Living with classical galactosemia: health-related quality of life consequences. Pediatrics 2004, 113(5):e423-e428.
126. Lambert C., Boneh A. The impact of galactosaemia on quality of life-a pilot study. J. Inherit. Metab. Dis. 2004, 27(5):601-608.
127. Ridel K.R., Leslie N.D., Gilbert D.L. An updated review of the long-term neurological effects of galactosemia. Pediatr. Neurol. 2005, 33(3):153-161.
128. Waisbren S.E., et al. Effect of expanded newborn screening for biochemical genetic disorders on child outcomes and parental stress. JAMA 2003, 290(19):2564-2572.
129. Waisbren S.E., et al. Brief report: predictors of parenting stress among parents of children with biochemical genetic disorders. J. Pediatr. Psychol. 2004, 29(7):565-570.
130. Leslie N.D., et al. A mouse model of galactose-1-phosphate uridyl transferase deficiency. Biochem. Mol. Med. 1996, 59(1):7-12.
131. Fitzgerald J., Bateman J.F. Why mice have lost genes for COL21A1, STK17A, GPR145 and AHRI: evidence for gene deletion at evolutionary breakpoints in the rodent lineage. Trends Genet. 2004, 20(9):408-412.
132. Lai K., et al. ARHI: a new target of galactose toxicity in classic galactosemia. Biosci. Hypotheses 2008, 1(5):263-271.